CRTX News and Press, Cortexyme Inc. From 09/26/19

Cortexyme ( CRTX -1.7% ) commences patient screening in Europe for its Phase 2/3 GAIN  study evaluating lead candidate COR388 for the potential treatment of mild-to-moderate Alzheimer's disease. More news on: Cortexyme, Inc., Healthcare stocks news, Read more ...

- International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer’s disease - GAIN Trial opened for U.S. enrollment in Q2 2019 and is expected to include approximately 90 sites globally ...

Bellus Health ( BLUSF ) could have its shares soon trading on the NASDAQ exchange. This is a very favourable announcement. As a result, we believe that market liquidity will increase, which may push the share price of Bellus up. We are positive on the stock. Another stock catalyst, which may e...

-- Presentation to be webcast on Cortexyme’s website Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, toda...

-- Rationale and design of the GAIN trial discussed in AAIC news briefing earlier this morning -- In Phase 1b testing, COR388 was associated with reductions in markers of inflammation and pathological ApoE fragmentation Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentati...

Noteworthy events during the week of July 14 - 20 for healthcare investors. More news on: ProMIS Neurosciences, Inc., Cortexyme, Inc., Cytori Therapeutics, Inc., Healthcare stocks news, , Read more ...

- Company’s novel approach to addressing Alzheimer’s to be featured in two Developing Topics abstracts at AAIC Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzhei...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board...

Gainers:  MoneyGram International (NASDAQ: MGI ) +106% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +33% . G1 Therapeutics (NASDAQ: GTHX ) +26% . SunPower Corporation (NASDAQ: SPWR ) +24% . Sundance Energy Australia (NASDAQ: SNDE ) +20% . Cortexyme (NASDAQ: CRTX...

Company Overview Cortexyme ([[CRTX]]) is a clinical-stage biopharmaceutical company pioneering a new disease-modifying therapeutic approach to treating Alzheimer’s disease and other neuro-degenerative diseases. The company is targeting a specific pathogen found in the brain of Alzhe...